A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

被引：25
|
作者：
Thondam, S. K. [1 ]
Cuthbertson, D. J. [1 ]
Aditya, B. S. [1 ]
MacFarlane, I. A. [1 ]
Wilding, J. P. [1 ]
Daousi, C. [1 ]
机构：
[1] Univ Liverpool, Dept Obes & Endocrinol, Aintree Univ Hosp NHS Fdn Trust Liverpool, Liverpool L69 3BX, Merseyside, England
来源：
CLINICAL ENDOCRINOLOGY | 2012年 / 77卷 / 04期
关键词：
FOOD-INTAKE; WEIGHT; HUMANS; DAMAGE;
D O I：
10.1111/j.1365-2265.2012.04368.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：635 / 637
页数：3
相关论文
共 50 条
  • [1] ALBIGLUTIDE Glucagon-Like Peptide GLP-1 Receptor Agonist Treatment of Type 2 Diabetes
    Rosenstock, Julio
    Stewart, Murray W.
    DRUGS OF THE FUTURE, 2010, 35 (09) : 701 - 712
  • [2] Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity
    Van Schaik, Jiska
    Begijn, Dominique G. A.
    Van Iersel, Laura
    Vergeer, Yvonne
    Hoving, Eelco W.
    Peeters, Babette
    Van Santen, Hanneke M.
    OBESITY FACTS, 2020, 13 (04) : 361 - 370
  • [3] Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiation
    Punjabi, Mukesh
    Arnold, Myrtha
    Geary, Nori
    Langhans, Wolfgang
    Pacheco-Lopez, Gustavo
    PHYSIOLOGY & BEHAVIOR, 2011, 105 (01) : 71 - 76
  • [4] Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients
    ten Kulve, Jennifer S.
    van Bloemendaal, Liselotte
    Balesar, Rawien
    IJzerman, Richard G.
    Swaab, Dick F.
    Diamant, Michaela
    la Fleur, Susanne E.
    Alkemade, Anneke
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (05) : 2122 - 2129
  • [5] Elevated Glucagon-like Peptide-1 Receptor Level in the Paraventricular Hypothalamic Nucleus of Type 2 Diabetes Mellitus Patients
    Renner, Eva
    Dora, Fanni
    Oszwald, Erzsebet
    Dobolyi, Arpad
    Palkovits, Miklos
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [6] Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
    Kopp, Katherine O.
    Glotfelty, Elliot J.
    Li, Yazhou
    Greig, Nigel H.
    PHARMACOLOGICAL RESEARCH, 2022, 186
  • [7] Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients
    Hopkins, N. D.
    Cuthbertson, D. J.
    Kemp, G. J.
    Pugh, C.
    Green, D. J.
    Cable, N. T.
    Jones, H.
    DIABETES OBESITY & METABOLISM, 2013, 15 (08) : 770 - 773
  • [8] Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity
    Golubic, Rajna
    Kennet, Jane
    Parker, Victoria
    Robertson, Darren
    Luo, Dan
    Hansen, Lars
    Jermutus, Lutz
    Ambery, Phil
    Ryaboshapkina, Maria
    Surakala, Manasa
    Laker, Rhianna C.
    Venables, Michelle
    Koulman, Albert
    Park, Adrian
    Evans, Mark
    DIABETES OBESITY & METABOLISM, 2024, 26 (07) : 2634 - 2644
  • [9] Cotadutide Dual glucagon-like peptide 1 receptor (GLP-1R)/glucagon receptor (GCGR) agonist Treatment of diabetes Treatment of nonalcoholic steatohepatitis Treatment of obesity
    Amblee, A.
    DRUGS OF THE FUTURE, 2020, 45 (11) : 799 - 811
  • [10] Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons
    Kawatani, Masahiro
    Yamada, Yuichiro
    Kawatani, Masahito
    PEPTIDES, 2018, 107 : 68 - 74
12345